A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD

Clinical trial NCT04931459 · COMPLETED

Trial details

NCT number: NCT04931459
Sponsor: Acumen Pharmaceuticals
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Alzheimer Disease

Start date: 2021-06-21
Primary completion: 2023-06-12
Enrollment: 65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.